Financial Comparison: Jushi (OTCMKTS:JUSHF) versus IceCure Medical (NASDAQ:ICCM)

Jushi (OTCMKTS:JUSHF) and IceCure Medical (NASDAQ:ICCM) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Volatility and Risk

Jushi has a beta of -0.63, suggesting that its stock price is 163% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.45, suggesting that its stock price is 55% less volatile than the S&P 500.

Institutional & Insider Ownership

21.7% of Jushi shares are held by institutional investors. Comparatively, 0.6% of IceCure Medical shares are held by institutional investors. 23.1% of Jushi shares are held by insiders. Comparatively, 2.4% of IceCure Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Jushi and IceCure Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Jushi	-24.44%	N/A	-15.46%
IceCure Medical	-427.67%	-174.26%	-112.58%

Analyst Ratings

This is a summary of recent ratings and target prices for Jushi and IceCure Medical, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jushi	0	0	1	0	3.00
IceCure Medical	2	0	3	0	2.20

IceCure Medical has a consensus target price of $52.50, indicating a potential upside of 2,223.01%. Given IceCure Medical’s higher possible upside, analysts clearly believe IceCure Medical is more favorable than Jushi.

Valuation and Earnings

This table compares Jushi and IceCure Medical”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jushi	$262.91 million	0.32	-$68.59 million	($0.34)	-1.22
IceCure Medical	$3.38 million	2.29	-$15.06 million	($8.52)	-0.27

IceCure Medical has lower revenue, but higher earnings than Jushi. Jushi is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Jushi beats IceCure Medical on 8 of the 14 factors compared between the two stocks.

About Jushi

Jushi Holdings Inc., a vertically integrated cannabis company, engages in the cultivation, processing, retail, and distribution of cannabis for medical and adult-use markets. The company offers flower, extracts, concentrates, edibles, oil, pre-rolls, tinctures, capsules, softgels, cannabis-infused gummies and ultra-premium chocolate, and topicals products, as well as vaporization devices and cartridges under The Bank, The Lab, Nira+ Medicinals, Sèchè, Tasteology, and Hijinks brands. It is also involved in the bulk wholesale of refined cannabinoids and terpenes. In addition, the company operates medical cannabis dispensaries under the BEYOND/HELLO, Nature’s Remedy, and NuLeaf brands. It markets its products to local dispensaries and large multi-state operators. The company is headquartered in Boca Raton, Florida.

About IceCure Medical

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.